Expert Ratings For Relay Therapeutics
Portfolio Pulse from Benzinga Insights
Relay Therapeutics (NASDAQ:RLAY) has been analyzed by 6 analysts in the last three months, showing a range of perspectives from bullish to bearish. The average 12-month price target is $18.67, down 5.85% from the previous $19.83. Analysts have recently lowered their price targets, reflecting evolving market conditions and company performance.
August 07, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Relay Therapeutics has received mixed analyst ratings with a 12-month price target average of $18.67, down 5.85% from the previous $19.83. Analysts have recently lowered their price targets, reflecting evolving market conditions and company performance.
The decrease in the average price target and the recent lowering of price targets by multiple analysts suggest a bearish short-term outlook for Relay Therapeutics. This reflects evolving market conditions and company performance, which could negatively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100